LBS-007 + venetoclax + azacitidine

**LBS-007 + venetoclax + azacitidine** is an investigational combination regimen under clinical development for the treatment of relapsed or resistant acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). - **LBS-007** is a selective, non-ATP competitive inhibitor of cell division cycle 7-related protein kinase (CDC7), which is essential for the initiation of DNA replication during the S phase of the cell cycle. By inhibiting CDC7, LBS-007 disrupts cancer cell proliferation and induces apoptosis, including in cells with p53 mutations[1][3][4][5][6][7]. - **Venetoclax** is a BCL2 inhibitor that promotes apoptosis by blocking the anti-apoptotic BCL2 protein. - **Azacitidine** is a DNA methyltransferase inhibitor that induces hypomethylation of DNA, leading to gene re-expression and cytotoxicity in abnormal hematopoietic cells. The combination aims to leverage LBS-007’s cell cycle inhibition, venetoclax’s pro-apoptotic mechanism, and azacitidine’s epigenetic modulation to enhance leukemia cell death, particularly in difficult-to-treat and chemotherapy-refractory cases[4]. This regimen is currently under investigation in phase 1/2 clinical trials for relapsed or resistant AML and ALL, with a particular focus on subpopulations with p53 mutations[3][4][7].

Other names

LBS-007LBS007LBS 007venetoclaxazacitidine